Related Experiment Videos

The role of Helicobacter pylori in cardiovascular and cerebrovascular diseases

A Gasbarrini1, F Cremonini, A Armuzzi

  • 1Medical Pathology, Universita Cattolica, Roma, Italy.

Journal of Physiology and Pharmacology : an Official Journal of the Polish Physiological Society
|March 1, 2000
PubMed

Insights

Helicobacter pylori infection may contribute to cardiovascular and cerebrovascular diseases. Further research is needed to confirm if H. pylori eradication improves outcomes in patients with vascular lesions.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Neurology

Background:

  • Cardiovascular and cerebrovascular disease prevalence is not fully explained by classical risk factors.
  • Chronic inflammation, a hallmark of atherosclerosis, may be linked to persistent infections.
  • Helicobacter pylori (H. pylori) is investigated for its potential role in these conditions.

Purpose of the Study:

  • To explore the potential link between H. pylori infection and ischemic events.
  • To review molecular mechanisms and epidemiological data regarding H. pylori and vascular diseases.
  • To assess the impact of H. pylori eradication on the clinical progression of vascular lesions.

Main Methods:

  • Review of epidemiological studies investigating H. pylori infection and cardiovascular/cerebrovascular diseases.
  • Analysis of proposed molecular mechanisms of H. pylori's action.
  • Evaluation of existing therapeutic studies on antibiotic treatment for ischemic heart disease.

Main Results:

  • Epidemiological studies suggest a possible correlation between H. pylori infection and vascular diseases.
  • Confounding factors complicate definitive conclusions from existing data.
  • Previous trials on antibiotic treatment for ischemic heart disease did not specifically assess H. pylori eradication's effect on vascular lesion progression.

Conclusions:

  • The role of H. pylori in cardiovascular and cerebrovascular diseases requires further investigation.
  • The impact of H. pylori eradication on the clinical progression of vascular lesions remains unaddressed by current research.
  • More targeted studies are needed to clarify the relationship and potential therapeutic benefits.

Related Concept Videos

Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...